Nls Pharmaceutics Ltd (NLSP)

Jun 16, 2025

NLS Pharmaceutics Announces Strategic Merger and Financing Milestones - TipRanks

Jun 16, 2025

Jun 16, 2025

NLS Pharmaceutics CEO Issues Letter to Shareholders - marketscreener.com

Jun 16, 2025

Jun 16, 2025

NLS Pharmaceutics Transforms: $25M Backing Powers Merger Deal as Company Goes Debt-Free - Stock Titan

Jun 16, 2025

Jun 10, 2025

NLS Pharmaceutics Announces June 2025 Shareholders’ Meeting Amid Financial Losses - TipRanks

Jun 10, 2025

Jun 06, 2025

NLS Pharmaceutics Amends Merger Agreement with Kadimastem - TipRanks

Jun 06, 2025

May 30, 2025

Short Interest in NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Decreases By 56.6% - Defense World

May 30, 2025

May 21, 2025

NLS Pharmaceutics to present Mazindol study at ASCP Meeting By Investing.com - Investing.com South Africa

May 21, 2025

May 21, 2025

NLS Pharmaceutics to present Mazindol study at ASCP Meeting - Investing.com Australia

May 21, 2025

May 21, 2025

NLS Pharmaceutics (NLSP) to Showcase Promising Data on Mazindol ER | NLSP Stock News - GuruFocus

May 21, 2025

May 21, 2025

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Ma - GuruFocus

May 21, 2025

May 21, 2025

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting - Nasdaq

May 21, 2025

May 21, 2025

Breakthrough Clinical Data: New Drug Shows Dual Action Against Fentanyl Addiction and Withdrawal - Stock Titan

May 21, 2025

May 14, 2025

NLS Pharmaceutics (NASDAQ:NLSP) Trading Down 0.6% – Should You Sell? - Defense World

May 14, 2025

May 05, 2025

NLS Pharmaceutics Extends Merger Agreement with Kadimastem - TipRanks

May 05, 2025

May 01, 2025

NLS Pharmaceutics Delays Yearly Report Filing - TipRanks

May 01, 2025

Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025

Apr 26, 2025

Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance - ACCESS Newswire

Apr 26, 2025

Apr 25, 2025

NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules - ACCESS Newswire

Apr 25, 2025

Apr 25, 2025

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split - ACCESS Newswire

Apr 25, 2025

Apr 24, 2025

NLS Pharmaceutics Announces Board Resignation Amid Restructuring Efforts - TipRanks

Apr 24, 2025

Apr 18, 2025

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics (PR Newswire) - Aktiellt

Apr 18, 2025

Apr 18, 2025

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS (PR Newswire) - Aktiellt

Apr 18, 2025

Apr 16, 2025

NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine

Apr 16, 2025

Apr 15, 2025

NLS Pharmaceutics Study Suggests Mazindol May Help Treat Fentanyl Use Disorder - marketscreener.com

Apr 15, 2025

Apr 15, 2025

NLS Pharmaceutics (NLSP): Promising Preclinical Results for Mazi - GuruFocus

Apr 15, 2025

Apr 15, 2025

NLS Pharmaceutics Reports Positive Results in Fentanyl Study - TipRanks

Apr 15, 2025

Apr 15, 2025

Nls Pharmaceutics Announces Positive Results From Study Ko-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward In Animal Models - MarketScreener

Apr 15, 2025

Apr 15, 2025

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models - Quantisnow

Apr 15, 2025

Apr 15, 2025

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models (PR Newswire) - Aktiellt

Apr 15, 2025

Apr 14, 2025

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics - ADVFN

Apr 14, 2025

Apr 06, 2025

NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest - ACCESS Newswire

Apr 06, 2025

Apr 03, 2025

NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN

Apr 03, 2025

Apr 02, 2025

Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - ACCESS Newswire

Apr 02, 2025

Mar 31, 2025

What's Going On With NLS Pharmaceutics Shares Monday? - Benzinga

Mar 31, 2025

Mar 31, 2025

NLS Pharmaceutics Secures $3 Million Financing and $25 Million Equity Facility - TipRanks

Mar 31, 2025

Mar 31, 2025

NLS Pharmaceutics secures $2M for Kadimastem merger - Investing.com

Mar 31, 2025

Mar 31, 2025

NLS Pharmaceutics secures $2M for Kadimastem merger By Investing.com - Investing.com Canada

Mar 31, 2025

Mar 31, 2025

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - StreetInsider

Mar 31, 2025

Mar 25, 2025

NLSP stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

NLSP stock touches 52-week low at $1.47 amid market challenges - Investing.com India

Mar 25, 2025

Mar 16, 2025

NLS Pharmaceutics Ltd. (NASDAQ:NLSPW) Short Interest Down 31.6% in February - Defense World

Mar 16, 2025

Mar 10, 2025

NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com Canada

Mar 10, 2025

Mar 10, 2025

NLS Pharmaceutics Announces Strategic Merger and Advances in Therapeutic Pipeline - TipRanks

Mar 10, 2025

Mar 10, 2025

NLS Pharmaceutics announces merger with Kadimastem - Investing.com India

Mar 10, 2025

Mar 05, 2025

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - Marketscreener.com

Mar 05, 2025

Mar 04, 2025

NLSP stock touches 52-week low at $1.71 amid steep annual decline - Investing.com

Mar 04, 2025

Mar 04, 2025

NLSP stock touches 52-week low at $1.71 amid steep annual decline By Investing.com - Investing.com South Africa

Mar 04, 2025